Andrea Reinecke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrea Reinecke has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
- Catherine J. Harmer
University of Oxford
11 shared publications Mike Rinck
Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands
10 shared publicationsLorika Shkreli
Department of Psychiatry, University of Oxford, UK
8 shared publicationsMichael Browning
Department of Psychiatry, University of Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, United Kingdom
8 shared publications- Michael Browning
Department of Psychiatry, University of Oxford, Oxford, UK
8 shared publications Eni S. Becker
7 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Research Square
Striatal tissue iron in depressed and healthy individuals and the effect of buproprion
Introduction: Dopaminergic dysfunction in the striatum is thought to play a central role in anhedonia in major depressive disorder (MDD). Normalised T2*-weighted (nT2*w) imaging provides a widely available MRI-derived proxy of striatal tissue iron, an indirect marker of dopaminergic function, but its relationship with reward processing and anhedonia in MDD has not been established. In this secondary analysis, we examined whether striatal nT2*w distinguishes individuals with MDD from healthy controls, is associated with reward learning and clinical symptoms, including anhedonia and depression, and is sensitive to treatment with the dopaminergic antidepressant bupropion Methods Depressed (n = 40) and healthy participants (n = 41) underwent clinical assessment, functional MRI, and a probabilistic instrumental learning task (PILT) at baseline, with follow-up assessments after 2 and 6 weeks. Participants with MDD received open-label bupropion treatment throughout the 6-week study. The primary outcome was MRI-derived striatal tissue iron, quantified using nT2*w signal extracted from resting-state fMRI within the whole striatum, caudate, putamen, and nucleus accumbens. Associations between nT2*w, diagnostic group, reward learning, clinical symptoms, and treatment response were examined. Results At baseline, depressed participants compared to healthy controls showed significantly higher striatal and caudate nT2*w values, indicative of lower tissue iron. The marker demonstrated excellent 2-week test-retest reliability in healthy participants. Striatal nT2*w was not associated with reward learning, anhedonia, or depression severity at baseline, and did not change following 2 weeks of bupropion treatment or predict clinical response after 6 weeks. Across groups, females demonstrated higher nT2*w values (lower tissue iron) than males in the striatum, caudate, and putamen. Discussion Striatal nT2*w represents a promising, robust and widely accessible neuroimaging marker of depression, reliably distinguishing depressed individuals from healthy controls while demonstrating excellent test–retest reliability. Larger longitudinal studies are now needed to establish its clinical utility and determine whether it can detect changes in reward processing and treatment response across the course of illness.
- 16 October 2026
- Published by Springer Nature in Research Square
Open AccessStriatal tissue iron in depressed and healthy individuals and the effect of buproprion
Introduction: Dopaminergic dysfunction in the striatum is thought to play a central role in anhedonia in major depressive disorder (MDD). Normalised T2*-weighted (nT2*w) imaging provides a widely available MRI-derived proxy of striatal tissue iron, an indirect marker of dopaminergic function, but its relationship with reward processing and anhedonia in MDD has not been established. In this secondary analysis, we examined whether striatal nT2*w distinguishes individuals with MDD from healthy controls, is associated with reward learning and clinical symptoms, including anhedonia and depression, and is sensitive to treatment with the dopaminergic antidepressant bupropion Methods Depressed (n = 40) and healthy participants (n = 41) underwent clinical assessment, functional MRI, and a probabilistic instrumental learning task (PILT) at baseline, with follow-up assessments after 2 and 6 weeks. Participants with MDD received open-label bupropion treatment throughout the 6-week study. The primary outcome was MRI-derived striatal tissue iron, quantified using nT2*w signal extracted from resting-state fMRI within the whole striatum, caudate, putamen, and nucleus accumbens. Associations between nT2*w, diagnostic group, reward learning, clinical symptoms, and treatment response were examined. Results At baseline, depressed participants compared to healthy controls showed significantly higher striatal and caudate nT2*w values, indicative of lower tissue iron. The marker demonstrated excellent 2-week test-retest reliability in healthy participants. Striatal nT2*w was not associated with reward learning, anhedonia, or depression severity at baseline, and did not change following 2 weeks of bupropion treatment or predict clinical response after 6 weeks. Across groups, females demonstrated higher nT2*w values (lower tissue iron) than males in the striatum, caudate, and putamen. Discussion Striatal nT2*w represents a promising, robust and widely accessible neuroimaging marker of depression, reliably distinguishing depressed individuals from healthy controls while demonstrating excellent test–retest reliability. Larger longitudinal studies are now needed to establish its clinical utility and determine whether it can detect changes in reward processing and treatment response across the course of illness.
- Open Access
- 15 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-8
Acute effects of AT1 receptor blockade on approach-avoidance of negative emotional faces
Recent evidence implicates the renin angiotensin system (RAS) in various cognitive markers of depression, including dysfunctional reward processing. Yet, it remains unknown whether these effects extend to other markers implicated in depression and its treatment, such as approach-avoidance motivations that reflect innate drives to approach reward and evade harm. We sought to examine the impact of acute losartan, an angiotensin type 1 (AT 1 ) receptor blocker, on the implicit approach-avoidance of facial expressions and checkerboard controls in healthy adults. In a randomized controlled trial, N = 68 healthy adults aged 18–50 (49 F/19 M) were administered a single 50 mg dose of losartan or placebo before completing an implicit Approach Avoidance Task (AAT) at drug-peak level. On the AAT, participants responded to color-filtered facial stimuli (happy, sad, angry, or neutral) and checkerboard controls using a joystick, and were instructed to pull all gray photos and push all brown photos as quickly as possible. Compared to placebo, losartan induced a significant avoidance bias for sad faces ( p = 0.027) and reduced avoidance of angry faces at trend level ( p = 0.085). This occurred without significant group differences on blood pressure, overall reaction time, accuracy, and approach-avoidance biases for other stimuli. The response pattern associated with AT 1 receptor blockade may counteract previously observed depressive tendencies, suggesting effects possibly consistent with antidepressant treatments. Our findings further highlight the RAS as a mechanistically relevant target for psychiatry, suggesting that AT 1 receptor antagonism may have relevance for treating depression and other emotional disorders characterized by aberrant motivational biases (Clincialtrials.gov ID: NCT06624904).
- 15 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-8
Open AccessAcute effects of AT1 receptor blockade on approach-avoidance of negative emotional faces
Recent evidence implicates the renin angiotensin system (RAS) in various cognitive markers of depression, including dysfunctional reward processing. Yet, it remains unknown whether these effects extend to other markers implicated in depression and its treatment, such as approach-avoidance motivations that reflect innate drives to approach reward and evade harm. We sought to examine the impact of acute losartan, an angiotensin type 1 (AT 1 ) receptor blocker, on the implicit approach-avoidance of facial expressions and checkerboard controls in healthy adults. In a randomized controlled trial, N = 68 healthy adults aged 18–50 (49 F/19 M) were administered a single 50 mg dose of losartan or placebo before completing an implicit Approach Avoidance Task (AAT) at drug-peak level. On the AAT, participants responded to color-filtered facial stimuli (happy, sad, angry, or neutral) and checkerboard controls using a joystick, and were instructed to pull all gray photos and push all brown photos as quickly as possible. Compared to placebo, losartan induced a significant avoidance bias for sad faces ( p = 0.027) and reduced avoidance of angry faces at trend level ( p = 0.085). This occurred without significant group differences on blood pressure, overall reaction time, accuracy, and approach-avoidance biases for other stimuli. The response pattern associated with AT 1 receptor blockade may counteract previously observed depressive tendencies, suggesting effects possibly consistent with antidepressant treatments. Our findings further highlight the RAS as a mechanistically relevant target for psychiatry, suggesting that AT 1 receptor antagonism may have relevance for treating depression and other emotional disorders characterized by aberrant motivational biases (Clincialtrials.gov ID: NCT06624904).
- Open Access
- 26 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
The relationship between renin-angiotensin system-modulating medication and depression: a systematic review
Introduction: The renin-angiotensin system (RAS) is implicated in stress, inflammation, and reward-related neurobiology, and RAS inhibition shows antidepressant-like effects in preclinical models. Whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are associated with depression outcomes in adults remains uncertain. Methods: We searched MEDLINE, Embase, PsycINFO, APA PsycArticles, and AMED from inception to November 2024 for observational studies examining ACEI or ARB exposure and depression outcomes in adults. Risk of bias was assessed with the Quality in Prognosis Studies (QUIPS) tool. Due to methodological heterogeneity, no meta-analysis was performed, and findings were synthesised using structured direction of effect methods, with sensitivity synthesis restricted to studies at low risk of confounding. Results: Fifteen studies involving more than 7 million participants were included. Eight studies reported protective associations between ACEI or ARB exposure and depression outcomes, six found no clear association, and one linked data cohort reported a modest increase in major depressive disorder with angiotensin antagonist monotherapy compared with patients not receiving antihypertensive treatment. Protective associations were more common in large registry cohorts using clinician-coded outcomes, whereas studies using symptom scales or prescription-based proxies were more often null. Among studies with stronger confounding control, findings were mixed. Conclusion: Observational evidence suggests a modest protective association between ACEI or ARB exposure and depression outcomes. However, heterogeneity in exposure and outcome definitions, together with residual confounding, limits causal inference. Prospective studies using bias-resistant designs and improved characterisation of incident depression, and better characterisation of drug-specific exposure are needed.
- 26 June 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessThe relationship between renin-angiotensin system-modulating medication and depression: a systematic review
Introduction: The renin-angiotensin system (RAS) is implicated in stress, inflammation, and reward-related neurobiology, and RAS inhibition shows antidepressant-like effects in preclinical models. Whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are associated with depression outcomes in adults remains uncertain. Methods: We searched MEDLINE, Embase, PsycINFO, APA PsycArticles, and AMED from inception to November 2024 for observational studies examining ACEI or ARB exposure and depression outcomes in adults. Risk of bias was assessed with the Quality in Prognosis Studies (QUIPS) tool. Due to methodological heterogeneity, no meta-analysis was performed, and findings were synthesised using structured direction of effect methods, with sensitivity synthesis restricted to studies at low risk of confounding. Results: Fifteen studies involving more than 7 million participants were included. Eight studies reported protective associations between ACEI or ARB exposure and depression outcomes, six found no clear association, and one linked data cohort reported a modest increase in major depressive disorder with angiotensin antagonist monotherapy compared with patients not receiving antihypertensive treatment. Protective associations were more common in large registry cohorts using clinician-coded outcomes, whereas studies using symptom scales or prescription-based proxies were more often null. Among studies with stronger confounding control, findings were mixed. Conclusion: Observational evidence suggests a modest protective association between ACEI or ARB exposure and depression outcomes. However, heterogeneity in exposure and outcome definitions, together with residual confounding, limits causal inference. Prospective studies using bias-resistant designs and improved characterisation of incident depression, and better characterisation of drug-specific exposure are needed.
- Open Access
- 20 June 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 191, 107944
The effect of acute angiotensin receptor blockade on subjective and biological markers of stress response
- 20 June 2026
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 191, 107944
Open AccessThe effect of acute angiotensin receptor blockade on subjective and biological markers of stress response
- Open Access
- 2 March 2026
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 67 (4) , 1044-1050
Towards an Extended Cognitive Model of Moral Injury—The Role of Mental Defeat
Moral injury (MI) is a proposed syndrome that develops when someone is exposed to, participates in, or fails to prevent an action that fundamentally violates their moral code and results in maladaptive cognitions about oneself and humanity. Post‐traumatic stress disorder (PTSD) is a disorder based on maladaptive cognitions that develops following a traumatic event. Decades of PTSD research underscore that the experience of mental defeat, or the perception that one was completely defeated during the traumatic event, plays a significant role in the development and maintenance of PTSD. Less work, however, has been done to develop a cognitive model of MI and to understand how mental defeat plays a role in the underlying maladaptive cognitions. Understanding the cognitive model of MI is key to developing effective cognitive therapy. In this paper, we first examine the role of mental defeat in PTSD cognitive models and then compare the PTSD cognitive model to proposed cognitive models for MI. Based on these comparisons and overlapping symptomology, we suggest that mental defeat plays an important role in MI cognitive models.
- 2 March 2026
- Published by Wiley in Scandinavian Journal of Psychology
- Vol. 67 (4) , 1044-1050
Open AccessTowards an Extended Cognitive Model of Moral Injury—The Role of Mental Defeat
Moral injury (MI) is a proposed syndrome that develops when someone is exposed to, participates in, or fails to prevent an action that fundamentally violates their moral code and results in maladaptive cognitions about oneself and humanity. Post‐traumatic stress disorder (PTSD) is a disorder based on maladaptive cognitions that develops following a traumatic event. Decades of PTSD research underscore that the experience of mental defeat, or the perception that one was completely defeated during the traumatic event, plays a significant role in the development and maintenance of PTSD. Less work, however, has been done to develop a cognitive model of MI and to understand how mental defeat plays a role in the underlying maladaptive cognitions. Understanding the cognitive model of MI is key to developing effective cognitive therapy. In this paper, we first examine the role of mental defeat in PTSD cognitive models and then compare the PTSD cognitive model to proposed cognitive models for MI. Based on these comparisons and overlapping symptomology, we suggest that mental defeat plays an important role in MI cognitive models.
- Open Access
- 13 January 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2402-2417
Structural brain differences associated with panic disorder: an ENIGMA-Anxiety Working Group mega-analysis of 4924 individuals worldwide
Neuroanatomical findings on panic disorder (PD) are typically difficult to replicate, with inconsistent effects. These concerns prompted a paradigm shift towards large-scale collaborations, focused on harmonized data extraction and processing for robust examination of PD brain correlates. Hence, leveraging the largest-ever multi-site neuroimaging database on PD (Age: 10–66 years; global sites: 28), compiled by the ENIGMA-Anxiety Working Group, we report on cortical and subcortical differences in individuals with PD (N = 1146) versus healthy controls (HC: N = 3778). The analyses revealed lower thickness and smaller cortical surface area within fronto-temporo-parietal regions in PD (Cohen’s ds: −0.08–0.13), along with lower thalamic and caudate volumes (Cohen’s ds: −0.07–0.12). Diagnosis-by-age2 interactions (Cohen’s ds: 0.07–0.12) revealed lower thickness in individuals with PD compared to HC in certain regions during adulthood (25–55 years), with relative absence of such differences during youth (55 years). Finally, patient subgroup analyses showed that early disease onset (≤21 years) in PD was associated with larger lateral ventricles (Cohen’s ds: 0.31–0.38), whilst no medication, comorbidity, or severity effects were found. These findings lend support to neurocircuitry models of PD, which postulate differences within fronto-striato-limbic circuits and temporo-parietal regions. Moreover, findings highlight the potential importance of abnormal development and aging in neuroanatomical differences related to PD. Given its unprecedented scale, the current study is an important milestone towards identifying the structural brain correlates of PD.
- 13 January 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (5) , 2402-2417
Open AccessStructural brain differences associated with panic disorder: an ENIGMA-Anxiety Working Group mega-analysis of 4924 individuals worldwide
Neuroanatomical findings on panic disorder (PD) are typically difficult to replicate, with inconsistent effects. These concerns prompted a paradigm shift towards large-scale collaborations, focused on harmonized data extraction and processing for robust examination of PD brain correlates. Hence, leveraging the largest-ever multi-site neuroimaging database on PD (Age: 10–66 years; global sites: 28), compiled by the ENIGMA-Anxiety Working Group, we report on cortical and subcortical differences in individuals with PD (N = 1146) versus healthy controls (HC: N = 3778). The analyses revealed lower thickness and smaller cortical surface area within fronto-temporo-parietal regions in PD (Cohen’s ds: −0.08–0.13), along with lower thalamic and caudate volumes (Cohen’s ds: −0.07–0.12). Diagnosis-by-age2 interactions (Cohen’s ds: 0.07–0.12) revealed lower thickness in individuals with PD compared to HC in certain regions during adulthood (25–55 years), with relative absence of such differences during youth (55 years). Finally, patient subgroup analyses showed that early disease onset (≤21 years) in PD was associated with larger lateral ventricles (Cohen’s ds: 0.31–0.38), whilst no medication, comorbidity, or severity effects were found. These findings lend support to neurocircuitry models of PD, which postulate differences within fronto-striato-limbic circuits and temporo-parietal regions. Moreover, findings highlight the potential importance of abnormal development and aging in neuroanatomical differences related to PD. Given its unprecedented scale, the current study is an important milestone towards identifying the structural brain correlates of PD.
- Open Access
The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers
Introduction: Cognitive flexibility, defined as the ability to shift mental strategies when environmental demands change, may influence psychological well-being and psychiatric treatment outcomes. Emerging research increasingly implicates the renin angiotensin system (RAS) in cognition, yet its role in cognitive flexibility is inadequately understood. Methods: We conducted a double-masked trial with N=60 healthy adults aged 18-50. Participants were randomly assigned to receive a single 50 mg dose of losartan, an angiotensin II receptor blocker, or placebo. Following a waiting period, participants completed a task-switching paradigm as a measure of cognitive flexibility, which required dynamically categorizing arrows based on location or direction. Statistical analyses were conducted to determine group (losartan vs. placebo), task (location vs. direction), and switch (switching vs. repeating a task) effects on reaction time (RT) and accuracy independently. A composite bin score was also computed, integrating both RT and accuracy data. Results: All participants displayed the expected switch costs. While participants on losartan exhibited numerically superior RTs and accuracy, losartan did not significantly improve task-switching performance relative to placebo. This was confirmed by the bin score analysis, which indicated no benefit of losartan when RT and accuracy were considered together. An exploratory probe suggested that losartan improved accuracy on direction switch trials, indicating a potential drug effect under specific cognitive conditions. Conclusion: Overall, we found no significant benefits of losartan on task-switching in healthy adults. Our results may be explained by ceiling effects in our sample, which could have hindered the detection of group differences, or possibly reflect a negligible role for the RAS in cognitive flexibility.
Open AccessThe renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers
Introduction: Cognitive flexibility, defined as the ability to shift mental strategies when environmental demands change, may influence psychological well-being and psychiatric treatment outcomes. Emerging research increasingly implicates the renin angiotensin system (RAS) in cognition, yet its role in cognitive flexibility is inadequately understood. Methods: We conducted a double-masked trial with N=60 healthy adults aged 18-50. Participants were randomly assigned to receive a single 50 mg dose of losartan, an angiotensin II receptor blocker, or placebo. Following a waiting period, participants completed a task-switching paradigm as a measure of cognitive flexibility, which required dynamically categorizing arrows based on location or direction. Statistical analyses were conducted to determine group (losartan vs. placebo), task (location vs. direction), and switch (switching vs. repeating a task) effects on reaction time (RT) and accuracy independently. A composite bin score was also computed, integrating both RT and accuracy data. Results: All participants displayed the expected switch costs. While participants on losartan exhibited numerically superior RTs and accuracy, losartan did not significantly improve task-switching performance relative to placebo. This was confirmed by the bin score analysis, which indicated no benefit of losartan when RT and accuracy were considered together. An exploratory probe suggested that losartan improved accuracy on direction switch trials, indicating a potential drug effect under specific cognitive conditions. Conclusion: Overall, we found no significant benefits of losartan on task-switching in healthy adults. Our results may be explained by ceiling effects in our sample, which could have hindered the detection of group differences, or possibly reflect a negligible role for the RAS in cognitive flexibility.
- Open Access
- 24 November 2025
- Published by Center for Open Science in PsyArXiv
Depression and Reward Function in Adolescence and the Potential of Behavioural Activation as a Treatment: A Narrative Review
Depression in adolescence is associated with poorer outcomes than adult-onset depression. While effective treatment can prevent difficulties from persisting into adulthood, current interventions for adolescent depression are often limited in effectiveness, likely because they fail to address the specific mechanisms underlying depression during this developmental stage. Access to treatment for adolescents presents an additional challenge. Effective, practical, and targeted treatments are urgently needed. To achieve this, we must identify key mechanisms of adolescent depression and develop interventions that address them directly.Growing evidence highlights reward function as a key mechanism in adolescent depression. At the same time, research suggests that Behavioural Activation (BA), with its emphasis on reward-focused behavioural changes, may be an effective treatment for adolescents with depression. To integrate these lines of research, we used a narrative approach to synthesise cross-disciplinary literature on reward function and BA in adolescent depression.This review found encouraging evidence for the effectiveness, feasibility, and cost-effectiveness of BA in adolescents. BA also shows potential for those with co-occurring autism or anxiety. However, the mechanisms through which BA works in adolescence are still unknown, and questions remain on its optimal delivery. Further research is needed to clarify how reward function influences both adolescent depression and response to BA, as well as how adolescents themselves wish to engage with BA therapy.
- 24 November 2025
- Published by Center for Open Science in PsyArXiv
Open AccessDepression and Reward Function in Adolescence and the Potential of Behavioural Activation as a Treatment: A Narrative Review
Depression in adolescence is associated with poorer outcomes than adult-onset depression. While effective treatment can prevent difficulties from persisting into adulthood, current interventions for adolescent depression are often limited in effectiveness, likely because they fail to address the specific mechanisms underlying depression during this developmental stage. Access to treatment for adolescents presents an additional challenge. Effective, practical, and targeted treatments are urgently needed. To achieve this, we must identify key mechanisms of adolescent depression and develop interventions that address them directly.Growing evidence highlights reward function as a key mechanism in adolescent depression. At the same time, research suggests that Behavioural Activation (BA), with its emphasis on reward-focused behavioural changes, may be an effective treatment for adolescents with depression. To integrate these lines of research, we used a narrative approach to synthesise cross-disciplinary literature on reward function and BA in adolescent depression.This review found encouraging evidence for the effectiveness, feasibility, and cost-effectiveness of BA in adolescents. BA also shows potential for those with co-occurring autism or anxiety. However, the mechanisms through which BA works in adolescence are still unknown, and questions remain on its optimal delivery. Further research is needed to clarify how reward function influences both adolescent depression and response to BA, as well as how adolescents themselves wish to engage with BA therapy.
- Open Access
- 23 March 2025
- Published by Elsevier in Psychiatry Research
- Vol. 348, 116458
Angiotensin receptor blockade modulates resting state functional connectivity in the memory network rather than fear network – implications for posttraumatic stress disorder
- 23 March 2025
- Published by Elsevier in Psychiatry Research
- Vol. 348, 116458
Open AccessAngiotensin receptor blockade modulates resting state functional connectivity in the memory network rather than fear network – implications for posttraumatic stress disorder
- Open Access
- 23 January 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 375, 293-296
Acute angiotensin receptor blockade and mnemonic discrimination in healthy participants
- 23 January 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 375, 293-296
Open AccessAcute angiotensin receptor blockade and mnemonic discrimination in healthy participants